



Rigshospitalet
Onkologisk afdeling 5073
Blegdamsvej 9
2100 København Ø
Att.: Helle Pappot

Ballerup, 13.12.2016

Agreement on support to: App development for Telekræftværket

Parties

Pfizer ApS (hereafter referred to as "Pfizer") wishes to provide support for development of app for Telekræftværket to support young patients with cancer and has therefore entered into this Agreement with Rigshospitalet, Onkologisk afdeling (hereafter referred to as the "Hospital").

Scope and purpose of the Agreement

The donation is given to provide support for development of app for Telekræftværket to support young patients with cancer.

The purpose of the activity is to provide easy accessibility to information and network for young patients with cancer.

Responsible persons at the Hospital

The donation will be given to Onkologisk Afdeling, Rigshospitalet and is approved by Klinikchef Hans von der Maase on behalf of Rigshospitalet.

Timeframe

The agreement shall run from 13.12.2016 to 13.12.2017.

Financial support

Pfizer's financial commitment in relation to this Agreement shall be 100.000,00 DKK excl. VAT.

Please complete and sign the attached Payment Form and return to Pfizer ApS as soon as possible together with the signed agreement. Please note that Pfizer will be precluded from providing you with the financial support if you do not state a CVR-number on the Payment Form.

Non-financial support

Pfizer will not provide any non-financial support.

Disclaimer

Onkologisk Afdeling, Rigshospitalet will ensure that the donation is used solely for professional and scientific purposes in relation to the activity and undertakes that any surplus from the donation not used in accordance herewith will be refunded.

Upon request from Pfizer the Hospital must document that the support is spend in accordance with the above-mentioned.

Furthermore Onkologisk Afdeling, Rigshospitalet will be responsible for compliance with all applicable law.

Pfizer shall not be liable for damages of any kind and Pfizer provides no indemnification of any type.

Disclosure

This Agreement shall be publicly disclosed on Pfizer's webpage (www.pfizer.dk) when the Agreement is made and for a period of 2 years thereafter.

Data Privacy

Information regarding name and contact information in relation to this agreement will be stored in a Pfizer global electronic system. You should be aware that some of the members of Pfizer group, legal counsel and/or regulatory authorities could have access to information as described above are located in countries whose laws protecting personal information may not be equivalent to those in your country. In particular, personal data disclosed to Pfizer Inc. by members of the Pfizer group within the European Economic Area and Switzerland are protected by Pfizer Inc.'s participation in the "safe harbour" schemes administered by the U.S. Department of Commerce.

You have right to access or, where incorrect, amend information pertaining to you that is in Pfizer's possession.

The support is provided under the provisions set forth in this agreement and in accordance with Pfizer's Representations and Warranties (Appendix A).

By signing this Agreement you confirm to have read and understood Pfizer's Representations and Warranties pursuant to Appendix A ("Representations and Warranties") and that the support is spend in accordance with the above mentioned terms and conditions.


Date: 18/12/2016
Signature of authorized signatory on behalf of Pfizer ApS:


Name: Stefano Podesta
Title: BU Head Oncology

Date: 20/12/2016
Signature of authorized signatory on behalf of Rigshospitalet:


Name: Hans von der Maase
Title: Klinikchef

Date: 12/1 2017
Signature of authorized signatory on behalf of Pfizer ApS:


Name: Per E. Jørgensen
Title: Managing Director
Per E. Jørgensen
Deputy Chief Executive, M.D., D.M.Sc.,
MPM RIGSHOSPITALET
Section 9921
Blegdamsvej 9 DK-2100 Copenhagen
Denmark

Date:
Signature of authorized signatory on behalf of Rigshospitalet:


Name: Helle Pappot
Title: Overlæge

Appendix A - Representations and Warranties

- 1.1 The financial support from Pfizer will not cause your entity and, to your knowledge, any individuals affiliated with your entity or this support, to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper business advantage;
- 1.2 Neither your entity nor, to your knowledge, any individuals affiliated with your entity or this support, will use any portion of the financial support from Pfizer to directly or indirectly offer or pay any money or anything of value in an effort to influence any Government Official or any other person in order for Pfizer to improperly obtain or retain business or to gain an improper business advantage, and, have not accepted, and will not accept in the future, such a payment;
- 1.3 Pfizer may at any time publicly disclose that it has provided you with financial support, including the amount of such support; and
- 1.4 Pfizer will be entitled to revoke or suspend any financial support if Pfizer learns that your entity or any individuals affiliated with your entity or this support has used or intends to use any portion of the support to improperly seek to influence any Government Official or any other person in order to obtain or retain business or gain a business advantage.